WuXi PharmaTech Climbs As Goldman Starts Coverage

 

NEW YORK (AP) — Shares of WuXi PharmaTech Cayman Inc. rose Thursday after a Goldman Sachs analyst started coverage of the stock with a "Buy" rating, and placed WuXi on a list of recommended stocks.

Profits should keep growing over the next two years for the Shanghai-based research and development outsourcing company, said analyst Wei Du. Du said WuXi is in a better competitive position than its rivals, and China may become a top research outsourcing market for drugmakers in developing countries.

He put the stock on the "Conviction Buy List," and WuXi shares gained $1.25, or 10.3 percent, to $13.40 in afternoon trading.

Du said laboratory service revenue should keep growing, while the toxicology service and manufacturing service businesses have good potential over the coming years.

"We see strong potential for growth in WuXi's manufacturing business in the long term, given its reputation and service quality," he wrote.

  • Loading Comments...
  •  

SHARE:

  • email
  • print
  • comment
  • digg
  • delicious
  • linkedin
Copyright 2009 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Recent Comments





Connect with TheStreet

Dow Jones S&P 500 NASDAQ 10-Year Note
10,464.40 1,110.63 2,176.05 32.79
Oil *
78.36
UP
30.69
UP
4.98
UP
6.87
DOWN
0.38
10 Yr
3.28%
SPDR Gold
116.62
+0.29%
+0.45%
+0.32%
-1.15%
Data delayed 20 minutes

Brokerage Partners

TheStreet Premium Services

All Services